Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Blocklisting Interim Review

1 Dec 2014 14:00

RNS Number : 4712Y
AstraZeneca PLC
01 December 2014
 



 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 1 DECEMBER 2014

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 JUNE 2014

To:

30 NOVEMBER 2014

Balance of unallotted securities under scheme(s) from previous return:

6,135,870

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

390,252

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,745,618

 

Name of contact:

MARTIN BENNETT

Telephone number of contact:

020 7604 8157

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRQKDDNDBDDPBK
Date   Source Headline
14th Sep 20177:00 amRNSAspen acquires remaining rights to AZ anaesthetics
11th Sep 20177:00 amRNSTagrisso potential standard of care in lung cancer
11th Sep 20177:00 amRNSIMFINZI superior PFS in Stage III lung cancer
7th Sep 201712:39 pmRNSCelgene and AZ update on Fusion trial programme
7th Sep 20177:00 amRNSAZ Duaklir improves lung function in COPD patients
7th Sep 20177:00 amRNSAZ tezepelumab cuts exacerbations in severe asthma
5th Sep 20177:00 amRNSDirectorate Change
1st Sep 20173:00 pmRNSTotal Voting Rights
29th Aug 20177:00 amRNSFaslodex gets US FDA OK for expanded use in breast
18th Aug 20177:00 amRNSLynparza gets broad FDA approval in ovarian cancer
16th Aug 20177:00 amRNSDirectorate Change
14th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20171:30 pmRNSPublication of a Prospectus
2nd Aug 20177:00 amRNSAZ acalabrutinib submission accepted by US FDA
1st Aug 20173:00 pmRNSTotal Voting Rights
1st Aug 20177:00 amRNSBTD for AZ's acalabrutinib in mantle cell lymphoma
31st Jul 20177:00 amRNSImfinzi granted BTD by US FDA for Stage III nsclc
28th Jul 201711:00 amRNSDirector/PDMR Shareholding
27th Jul 20177:15 amRNSTagrisso significantly improves FLAURA
27th Jul 20177:11 amRNSAZ reports initial results from MYSTIC lung trial
27th Jul 20177:06 amRNSAZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27th Jul 20177:00 amRNSAstraZeneca PLC - H1 2017 Results
26th Jul 20174:46 pmRNSFaslodex receives EU approval for 1L breast cancer
21st Jul 20173:45 pmRNSHolding(s) in Company
3rd Jul 20172:59 pmRNSTotal Voting Rights
3rd Jul 20177:00 amRNSAZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
3rd Jul 20177:00 amRNSAZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23rd Jun 201712:46 pmRNSFaslodex CHMP positive opinion in 1L breast cancer
7th Jun 20177:13 amRNSAZ agreement with Grünenthal for rights to Zomig
6th Jun 20177:00 amRNSASTRAZENECA PRICES A $2BN BOND ISSUE
5th Jun 20177:00 amRNSLYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
1st Jun 20173:00 pmRNSBlock listing Interim Review
1st Jun 20173:00 pmRNSTotal Voting Rights
31st May 20177:00 amRNSDirectorate Change
24th May 20173:00 pmRNSDirector/PDMR Shareholding
23rd May 20177:00 amRNSBydureon EXSCEL trial meets T2D safety objective
22nd May 20177:00 amRNSAZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16th May 20173:00 pmRNSDirector/PDMR Shareholding
12th May 20177:00 amRNSIMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10th May 20177:00 amRNSAZ updates on tralokinumab trial in severe asthma
2nd May 20172:00 pmRNSTotal Voting Rights
2nd May 20177:00 amRNSDURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27th Apr 20175:30 pmRNSResult of AGM
27th Apr 20177:00 amRNSAstraZeneca: Q1 2017 Results
25th Apr 20171:30 pmRNSTAGRISSO RECEIVES FULL APPROVAL IN THE EU
12th Apr 20175:34 pmRNSNotification of Major Interest in Shares
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20177:01 amRNSTagrisso (osimertinib) receives FDA full approval
31st Mar 20177:00 amRNSAZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28th Mar 20174:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.